Strata Critical Medical (SRTA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, with voting open until May 27, 2026 at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 14, 2026.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of Class II Directors for terms expiring in 2029, with nominees William A. Heyburn and Andrew Lauck.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026.
Advisory vote on the compensation of named executive officers (say-on-pay).
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and auditor ratification.
Latest events from Strata Critical Medical
- Proxy covers director elections, auditor ratification, and executive pay amid a strategic business shift.SRTA
Proxy filing14 Apr 2026 - Q4 2025 revenue soared 83.5% YoY, with 2026 guidance raised on strong growth and integration.SRTA
Q4 20253 Mar 2026 - Q2 2024 delivered 11.4% revenue growth, positive Adjusted EBITDA, and record Medical results.SRTA
Q2 20242 Feb 2026 - Q3 revenue up 5% to $74.9M, Medical leads growth, margins and liquidity strong, outlook positive.SRTA
Q3 202414 Jan 2026 - Rapid growth in medical logistics and early passenger profitability set the stage for eVTOL-driven expansion.SRTA
UBS Global Technology and AI Conference11 Jan 2026 - Rapid growth in medical logistics and urban air mobility, with profitability expected in 2024.SRTA
27th Annual Needham Growth Conference10 Jan 2026 - Focused on medical logistics growth, leveraging tech, partnerships, and cost efficiency.SRTA
Jefferies Mining and Industrials Conference 202531 Dec 2025 - Profitability reached, with medical leading growth and strong positioning for the eVTOL future.SRTA
J.P. Morgan Industrials Conference 202526 Dec 2025 - First full year of Adjusted EBITDA profitability, with 10% revenue growth and margin gains.SRTA
Q4 202424 Dec 2025